English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/214138
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients

AuthorsCubillos-Zapata, Carolina; Martinez-Garcia, Cristina; Campos-Rodríguez, Francisco; Sánchez de la Torre, Manuel; Nagore, Eduardo; Martorell-Calatayud, Antonio; Hernández Blasco, Luis; Chiner, Eusebi; Abad-Capa, Jorge; Montserrat, Josep M. ; Cabriada-Nuño, Valentín; Cano-Pumarega, Irene; Corral-Peñafiel, Jaime; Díaz-Cambriles, Trinidad; Mediano, Olga; Somoza, María; Dalmau-Arias, Joan; Almendros, Issac; Farre, Ramón; López-Collazo, Eduardo; Gozal, David; García-Río, Francisco
Issue Date2019
PublisherEuropean Respiratory Society
John Wiley & Sons
CitationEuropean Respiratory Journal 53(2): 1801298 (2019)
AbstractObstructive sleep apnoea (OSA) upregulates the programmed cell death-1 receptor and its ligand (PD-L1) pathway, potentially compromising immunosurveillance. We compared circulating levels of soluble PD-L1 (sPD-L1) in patients with cutaneous melanoma according to the presence and severity of OSA, and evaluated relationships with tumour aggressiveness and invasiveness. In a multicentre observational study, 360 patients with cutaneous melanoma underwent sleep studies, and serum sPD-L1 levels were assayed using ELISA. Cutaneous melanoma aggressiveness indices included mitotic rate, Breslow index, tumour ulceration, Clark level and tumour stage, and sentinel lymph node (SLN) metastasis was recorded as a marker of invasiveness. sPD-L1 levels were higher in severe OSA compared to mild OSA or non-OSA patients. In OSA patients, sPD-L1 levels correlated with Breslow index and were higher in patients with tumour ulceration, advanced primary tumour stages or with locoregional disease. The incorporation of sPD-L1 to the classic risk factors to SLN metastasis led to net improvements in the classification of 27.3%. Thus, sPD-L1 levels are increased in melanoma patients with severe OSA, and, in addition, might serve as a potential biomarker of cutaneous melanoma aggressiveness and invasiveness in this group of subjects.
Publisher version (URL)http://dx.doi.org/10.1183/13993003.01298-2018
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.